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Abstract
Objectives: The objectives of the study were to assess the main risk factors related 
to Epstein–Barr virus (EBV) infection on oral squamous cell carcinoma (OSCC) 
and the influence on its biological behavior. Methodology: A search for articles on 
EBV infection and mouth neoplasms was performed in the next electronic databases: 
PubMed (MEDLINE, Cochrane Library), Web of Science, and Spanish Medical Index 
(IME). From 600 potentially eligible articles, 575 were excluded for several reasons: 
Articles without full-text availability (201), studies on hairy leukoplakia (256), studies 
in patients without OSCC (42), studies on malignant salivary gland neoplasms (19), 
studies in HIV+ or immunocompromised patients (14), and studies with non-usable 
data (43). Finally, 25 studies were included in this meta-analysis. The statistical software 
RevMan 5.3 (The Cochrane Collaboration, Oxford, UK) was used to analyze the data. 
For dichotomous outcomes, the estimates of effects of an intervention were expressed 
as odds ratio (OR) using the Mantel-Haenszel method with 95% confidence intervals. 
Results: About 46.3% of oral cancers were infected with EBV. Oral cancer patients 
had more than triple the risk of being infected with EBV than controls (OR: 3.48, P = 
0.01). In contrast, age (>60 years), gender (women), tumor location (tongue-floor of 
the mouth), tumor differentiation degree (well differentiated), or tumor stage (III and 
IV) were parameters without significant influence (P > 0.05) in oral cancers infected 
with EBV.  Conclusion: EBV infection may be an important risk factor in oral cancer. 
Clinical Significance: Specific treatment of EBV infection can improve the biological 
behavior of oral cancers toward less aggressive tumors.
Keywords: Epstein–Barr virus infections, herpesvirus 4 human, mouth neoplasms, oral 
manifestations, prognosis, risk factors
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Introduction
Oral cancer has the ninth largest prevalence in males worldwide, 
being oral squamous cell carcinoma (OSCC) the most common 
histologic type with approximately 90% of cases. The main risk 
factors for OSCC remain the consumption of tobacco and/
or alcohol and, above all, the combined consumption of both. 
Other proposed etiological factors are infectious agents such as 
human papillomavirus (HPV), Candida species superinfection, 
or Epstein–Barr virus (EBV).[1]
EBV is a gamma-herpesvirus that infects both B lymphocytes 
and oral epithelial cells. Once the infection occurs, the subject 
is infected for life, and the host may be asymptomatic as the 
virus is in a dormant state. It is responsible for common benign 
processes such as infectious mononucleosis and is also associated 
with different types of malignancies such as lymphomas (Burkitt 
and Hodgkin) or carcinomas (nasopharyngeal, etc.).[2]
The real role of EBV infection in the development of OSCC 
remains unclear. The poor detection of EBV-DNA in OSCC 
compared to control groups could be explained by the so-called 
“hit and run theory,” where viral DNA would only act as an 
initiator and would decrease with the malignant transformation 
of cells. In this same sense, the expression of the latent membrane 
protein (LMP) of the EBV 1, the main oncoprotein of this virus 
is essential for the transformation of cells, but unnecessary in 
already transformed cells.[3]
EBV is in a latent status in all malignancies related to this virus. 
Viral latency allows sustained expression of viral oncogenes, 
remaining undetected by the host immune system. EBV infection 
may induce epigenetic changes and inheritable changes in gene 
expression that do not result from DNA mutations, in lymphoid 
and epithelial cells.
Epidemiological studies have revealed highly variable 
rates of EBV infection in OSCC, probably conditioned by 
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geographic and ethnic differences. EBV-positive OSCCs have 
been shown to have a worse tumor differentiation degree. EBV 
infection delays epithelial differentiation and promotes a more 
invasive phenotype of epithelial cells. Moreover, the delayed 
differentiation and the greater invasive capacity were maintained 
in epithelial cells even after the loss of EBV, indicating that 
stable epigenetic reprogramming followed EBV infection. Thus, 
EBV infection could contribute to the pathogenesis of OSCC 
by epigenetic reprogramming of infected neoplastic cells.[4] 
This study aimed to assess the main risk factors related to EBV 
infection on OSCC and the influence on its biological behavior.
Methodology
A search of studies on oral cancer and EBV was performed in the 
following databases: PubMed (MEDLINE, Cochrane Library), 
Web of Science (WoS), and the Information and Documentation 
of Science in Spain (InDICEs-CSIC) that include the Spanish 
Medical Index (IME). Search strategies included terms from 
Medical Subjects Headings (MeSH) and free text words such 
as “Epstein–Barr virus infections” OR “Epstein–Barr virus” 
AND “mouth neoplasms” OR “oral cancer.” A total of 1588 
articles were located (548 in PubMed, 1038 in WoS, and 2 in 
IME) between February 1964 and May 2018, 988 of them 
duplicates for having the same title and abstract, which left 600 
articles for review. The titles and abstracts of the studies were 
independently examined by two authors (ARA and KL) to 
evaluate eligibility, and subsequently, the possible discrepancies 
were resolved jointly. No restrictions regarding the sample 
size or the EBV detection method were established. Exclusion 
criteria were as follows: (a) Articles without full-text availability 
(n = 201), (b) studies on hairy leukoplakia (n = 256), (c) studies 
in patients without OSCC (n = 42), (d) studies in malignant 
salivary gland neoplasms (n = 19), (e) studies in HIV-positive 
or immunocompromised patients (n = 14), and (f) studies with 
non-usable data (n = 43). Finally, 25 studies were incorporated 
to this meta-analysis [Figure 1].
Statistical analysis
For the meta-analysis, the data were processed with the RevMan 
5.3 program (The Cochrane Collaboration, Oxford, UK). For 
dichotomous outcomes, the odds ratio (OR) was used with the 
Mantel-Haenszel Chi-square formula, and for the continuous 
ones, the inverse of the variance (IV) was used for the mean 
differences, both with 95% confidence intervals (95% CI). 
Heterogeneity was determined according to P values and the 
Higgins statistic (I2). The random effect model was applied in 
cases of high heterogeneity (I2>50%). P < 0.05 was considered 
as the minimum level of significance.
Results
Twenty-five studies[5-29] analyzed the prevalence of EBV 
detection in patients with oral cancer from 14 different countries 
[Table 1]. About 46.3% of oral cancer patients (722/1559) 
were infected with EBV, with frequencies ranging from 8.0% 
in India[26] in 2013 to 82.5% in Taiwan[18] in 2009. Regarding 
Figure 1: Study flow diagram
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EBV detection methods, 22 studies[5-15,17-25,27,29] (88%) used the 
polymerase chain reaction (PCR), and 3[16,26,28] (12%) used 
immunohistochemistry (IMH) techniques.
Table 2 presents the analysis of the main risk factors in OSCC 
patients infected with EBV.
Nineteen studies[5-7,10,12-17,19-22,24-26,28,29] examined the presence 
of EBV in OSCC patients and controls without the disease. 
OSCC patients had 3.51 times more likely to be infected with 
EBV, with statistically significant differences (OR = 3.51; 95% 
CI: 1.49–8.23; P < 0.01).
Eight studies[6,9,11,13,15,20,23,24] investigated the role of age 
on the risk of EBV infection, showing a slightly higher risk in 
subjects older than 60 years, although no statistically significant 
relationship was found (OR = 1.05; 95% CI: 0.66–1.55; 
P = 0.85). Other 10 studies[6,8,9,11,13,15,18,20,24,27] analyzed gender, 
confirming a higher probability of EBV infection in women than 
in men. However, no statistically significant association was 
observed (OR = 1.20; 95% CI: 0.77–1.86; P = 0.42).
Table 1: Studies on the prevalence of Epstein–Barr virus (EBV) in patients with oral cancer
First author Year Country Study type EBV detection method EBV+n/N (%)
van Heerden et al.[5] 1995 South Africa C-C PCR 13/48 (27.1)
Cruz et al.[6] 1997 Netherlands C-C PCR 18/36 (50.0)
D’Costa et al.[7] 1998 India C-C PCR 25/103 (24.3)
Maeda et al.[8] 1998 Japan CS PCR 29/45 (64.4)
Tsuhako et al.[9] 2000 Japan CS PCR 62/102 (60.8)
Gonzalez-Moles et al.[10] 2002 Spain CS PCR 15/78 (19.2)
Higa et al.[11] 2002 Japan CS PCR 39/54 (72.2)
Sand et al.[12] 2002 Sweden C-C PCR 11/29 (37.9)
Shimakage et al.[13] 2002 Japan C-C PCR 15/29 (51.7)
Szkaradkiewicz et al.[14] 2002 Poland CS PCR 8/14 (57.1)
Bagan et al.[15] 2008 Spain C-C PCR 6/11 (54.5)
Shamaa et al.[16] 2008 Egypt C-C IMH 18/22 (81.8)
Kis et al.[17] 2009 Hungary C-C PCR 48/65 (73.8)
Yen et al.[18] 2009 Taiwan CS PCR 47/57 (82.5)
Jalouli et al.[19] 2010 Sweden C-C PCR 69/217 (31.8)
Nola-Fuchs et al.[20] 2012 Croatia C-C PCR 11/24 (45.8)
Acharya et al.[21] 2015 Thailand C-C PCR 41/91 (45.1)
Jiang et al.[22] 2015 China C-C PCR 4/25 (16.0)
Polz-Gruszka et al.[23] 2015 Poland CS PCR 24/92 (26.1)
Bagan et al.[24] 2016 Spain C-C PCR 7/12 (58.3)
Kikuchi et al.[25] 2016 Japan C-C PCR 78/150 (52.0)
Reddy et al.[26] 2017 India C-C IMH 2/25 (8.0)
Shahrabi-Farahani et al.[27] 2018 Iran CS PCR 68/94 (72.3)
Rahman et al.[28] 2019 Thailand C-C IMH 22/36 (61.1)
Sharma et al.[29] 2019 India C-C PCR 42/100 (42.0)
Total 722/1559 (46.3)
C-C: Case–control study; CS: Cross-sectional study; PCR: Polymerase chain reaction; IMH: Immunohistochemistry
Table 2: Risk factors related to Epstein–Barr virus infection in 
patients with oral squamous cell carcinoma
Risk factor n Reference 
value
OR [95% CI] I2 (%) P-value
EBV detection 19 OSCC 3.51 [1.49–8.23] 91 <0.01*
Age 8 >60 yr 1.05 [0.66–1.65] 24 0.85
Gender 10 Female 1.20 [0.77–1.86] 0 0.42
Tumor 
location
11 T-FM 1.14 [0.78–1.67] 22 0.49
Tumor 
differentiation
6 WD 1.39 [0.88–2.19] 0 0.16
Tumor stage 5 III-IV 1.11 [0.68–1.83] 0 0.67
n: Number of studies; yr: Years; T-FM: Tongue-floor of mouth; WD: Well 
differentiated; OR: Odds ratio; [95%CI]: 95% confidence interval; I2: 
Higgins statistic for heterogeneity; *statistically significant
Eleven studies[6,8,9-11,13,15,18,20-22] evaluated the location of the 
tumor lesion. A greater number of EBV-infected tumors located 
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on the tongue or the floor of the mouth were reported, although 
without statistically significant differences (OR = 1.14; 95% 
CI: 0.78–1.67; P = 0.49).
Six studies[6,8,9,11,13,27] examined the possible influence of 
EBV infection on the tumor differentiation degree, finding 
a higher percentage of well-differentiated EBV-positive 
tumors. Nevertheless, a statistical significance was not reached 
(OR = 1.39; 95% CI: 0.88–2.19; P = 0.16). Five studies[9,11,13,20,27] 
analyzed the tumor stage, highlighting more EBV-infected 
tumors in more advanced stages (III-IV) but with no statistically 
significant relationship (OR = 1.11; 95% CI: 0.68–1.83; 
P = 0.67).
Discussion
Data from 25 studies have been included in the present meta-
analysis on the potential role of EBV infection in OSCC.
In the present study, the mean percentage of EBV detection 
in OSCC patients was 46.3%, a similar percentage to that found 
by de Lima et al.[30] with 45.37% and much lower than that 
observed by Kis et al.[17] with 73.08% detection of the virus in 
patients with oral cancer. The EBV detection rates were highly 
variable in the different studies, probably due to differences in 
methodologies or applied techniques (PCR, nested PCR, IMH, 
in situ hybridization, etc.) to detect EBV in OSCC samples. 
Fresh/frozen tissues showed a higher positivity rate to EBV than 
that expressed by paraffin-embedded tissues, although detection 
of viral DNA is easier and simpler in the latter.[3]
In this study, OSCC patients were 3.51 times more likely to be 
infected with EBV than controls with very significant statistical 
differences (P < 0.01). Fourteen studies[6,7,10,12-17,21,22,24,28,29] agreed 
with our results, observing a higher detection of EBV in patients 
with oral cancer, which could highlight a possible relationship 
between EBV and OSCC.
Once infected, EBV remains transcriptionally active, 
expressing so-called “latent genes.” This group of latent genes 
includes EBV-encoded RNAs, Epstein–Barr nuclear antigens 
(EBNAs), and LMPs.[4] Furthermore, EBV is capable of 
encoding some oncogenic proteins, especially the EBV LMP-1 
and the EBNA-2, which are essential for cell transformation and 
have a fundamental role in cell immortalization.[4] LMP-1 is an 
oncoprotein that plays a crucial role in cellular transformation 
through the inhibition of the differentiation of epithelial cells, 
favoring oral malignancy. LMP-1 is considered the most 
important gene because it increases the expression of anti-
apoptotic proteins in infected B cells, protecting them from 
p53-mediated apoptosis. It increases the expression of IL-10, 
which stimulates the proliferation of B cells and inhibits the local 
immune response.[4]
In contrast, four studies[5,19,20,25] disagreed with our findings, 
not evidencing a higher detection of EBV in patients with oral 
cancer, suggesting a lack of relationship. Some studies observed a 
higher expression in severe dysplastic lesions than in OSCCs,[25] 
others were carried out in population groups with very specific 
characteristics and with particular habits that do not allow the 
results to be extrapolated to the general population.[5,19] Finally, 
others pointed out that the presence of EBV in oral cancers 
could be a coincidental event rather than an etiological factor, 
especially if there is no coinfection with other viruses, such as the 
HPV.[20]
This study also analyzed the possible influence of 
epidemiological parameters (age and gender) on EBV infection 
in OSCC patients. Although a higher prevalence of EBV was 
observed in subjects older than 60 years and women, the 
results were not statistically significant (P = 0.85 and P = 0.42, 
respectively). The true influence of age on EBV infection is 
controversial with disparate results in different studies. Six 
studies[6,9,11,15,23,24] observed more EBV infections in those older 
than 60 years and, in contrast, another four,[9,11,13,20] in subjects 
younger than this age.
If with increasing age, the probability of having cancer 
increases, it seems logical that also at older age, greater probability 
of EBV infection. However, it should also be borne in mind that 
EBV is responsible for infectious mononucleosis, a characteristic 
disease of the young patient.[24]
The same occurs with gender, where the results were 
conflicting. Some studies[8,9,11,13,18,20,27] indicated a higher 
frequency in women and others[6,9,15,24] indicated a predilection 
for males. The carcinogenic effect of EBV in cancer patients is 
likely similar regardless of their gender.[27] Other factors involved 
in oral carcinogenesis should also be considered, such as tobacco 
and alcohol consumption, which, in principle, is higher in men.[24]
In the present study, the location of the tumor was also 
evaluated by comparing the locations with the highest risk 
(tongue/floor of the mouth) for their ability to spread with the 
rest of the oral locations. Although more EBV-positive tumors 
were located in these higher risk locations, no statistically 
significant differences were observed (P=0.49). As happened 
on previous occasions, the findings are very different. Six 
studies[9-11,13,18,22] indicated a greater location in the tongue and 
the floor of the mouth and another six,[8,9,11,15,20,21] indicated the 
rest of the oral locations as the most prevalent in EBV-positive 
tumors. These highly variable results are likely conditioned by 
the selection of patients with oral cancer. The most common 
oral cancer location is the lateral borders of the tongue and, in 
the case of oropharyngeal cancer, the tonsils, and the base of 
the tongue. Coinfection of HPV and EBV could explain this 
predilection for lingual location.[22] However, Acharya et al.[21] 
found the gingiva as the main location of EBV-positive tumors. 
This study was conducted in a group of patients who, in addition 
to the harmful habits of tobacco and alcohol consumption, 
were betel quid chewers. These authors observed a statistically 
significant relationship (P = 0.02) between virus infection and 
betel quid chewing, suggesting that EBV detection may be 
increased in OSCC patients.[21]
The possible influence of EBV infection on some tumor 
histopathological parameters such as the tumor differentiation 
degree and tumor stage was also analyzed in our study. Although a 
greater number of EBV-positive tumors were well-differentiated 
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and in more advanced stages (III-IV), statistical significance was 
not reached (P = 0.16 and P = 0.67, respectively).
These findings are highly conditioned by the different 
geographical areas where the studies were carried out the kind 
of job and the habits of these populations.[11] Another factor 
influencing differentiation and tumor staging is EBV and HPV 
coinfection. Infection with the latter virus is closely linked to 
orogenital sex practices. HPV-infected oral tumors tend to have 
better differentiation and a higher survival rate.[20]
New studies to determine the real influence of all these 
factors on EBV-infected oral tumors are needed.
Some limitations must be taken into account in the present 
study. First, the results of this meta-analysis, especially regarding 
the prevalence of EBV in patients with OSCC and controls, 
should be interpreted with caution due to the high heterogeneity 
observed. The differences between studies may be conditioned 
by the type of design and analysis, the different EBV detection 
techniques, or the particular characteristics of the study 
populations. Second, other sources of potential bias are the 
different techniques and methodologies used to EBV detection, 
the possible interlaboratory variability even if they use the same 
tests, the histological classification of tumor samples, or the use 
of different tissues as control samples. Third, studies with small 
sample sizes tend to overestimate their results and decrease their 
precision. Fourth, in some studies, there is little information 
on the characteristics of the control groups and others did not 
adequately evaluate different confounding factors (age, gender, 
harmful habits, etc.).
Conclusion
In this study, the mean EBV detection rate in patients with oral 
cancer was 46.3%. Oral cancer patients had more than 3 times 
greater risk of being infected with EBV than controls (OR: 
3.51; P < 0.01). On the other hand, age (>60 years), gender 
(women), location (tongue-floor of mouth), degree of tumor 
differentiation (well differentiated), or tumor stage (III and IV) 
were parameters without significant influence (P > 0.05) in EBV-
infected oral cancers.
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